RNA, U6 small nuclear 875, pseudogeneGenealiases: []
Q-omics provides the consensus-scored RNU6-875P profile across patient tissues and cancer cell-line models. RNU6-875P expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RNU6-875P is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, RNU6-875P RNA expression shows 11,560 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, HNSC, and GBM as cancer lineages where RNU6-875P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU6-875P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU6-875P survival associations across molecular data types. RNU6-875P RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU6-875P RNA expression–survival associations across cancer types. High RNU6-875P expression shows unfavorable associations in ACC, UCEC, THYM, KICH, CESC and KIRC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RNU6-875P RNA expression.
This table summarizes RNU6-875P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for RNU6-875P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU6-875P shows higher tumor expression in HNSC, LUSC, STAD, BRCA, UCEC and BLCA. The HNSC box plot shows higher RNU6-875P RNA expression in tumor versus normal tissue (log2 FC = +0.882, t-test p < 0.001).
This table shows molecular features associated with RNU6-875P in patient tissues and cancer cell lines. In patient samples, RNU6-875P shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
